A Phase 3, Randomized, Open-Label Study to Investigate the Efficacy and Safety of Once Daily Oral Orforglipron Compared With Dapagliflozin in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin (ACHIEVE-2)
A Phase 3, Randomized, Open-Label Study to Investigate the Efficacy and Safety of Once Daily Oral Orforglipron Compared With Dapagliflozin in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin (ACHIEVE-2)
The main purpose of this study is to assess the safety and efficacy of orforglipron compared with dapagliflozin in improving blood sugar control in participants with type 2 diabetes (T2D) with inadequate glycemic control using metformin. The study will last approximately 46 weeks.
Inclusion Criteria:
Exclusion Criteria:
Lingen, Lower Saxony 49808, Germany
Saint Ingbert, Saarland 66386, Germany
Cuauhtémoc, Ciudad de México, Mexico City 06100, Mexico
San Nicolás de los Garza, Nuevo León 66450, Mexico
Culiacán, Sinaloa 80230, Mexico
Krakow, Lesser Poland Voivodeship 31-261, Poland
Wroclaw, Lower Silesian Voivodeship 50-162, Poland
Lodz, Łódź Voivodeship 90-338, Poland
Kaohsiung Niao Sung Dist, Kaohsiung 83301, Taiwan